Aclaris Therapeutics

Aclaris presented at the Cantor Fitzgerald Healthcare Conference a development plan focused on bispecific antibodies, ITK programs and lichen planus. The company expects multiple Phase‑1b readouts within nine months, including ATI‑052 in asthma and atopic dermatitis, and plans to start a lichen planus study; with positive interim data, regulatory discussions could be possible in 1H 2027. Management says cash on hand is sufficient through the end of 2028 to fund asthma, lichen planus, EoE proof‑of‑concept work and both ITK programs, but the Phase‑2b study in atopic dermatitis is only partially funded, so additional capital is likely required. » Więcej na de.investing.com

Stifel reiterated a Hold on Aclaris Therapeutics and raised its price target to $4, citing optimism about the company’s multi-targeting immunology approaches. Aclaris reported positive Phase 1a SAD/MAD results for bispecific antibody ATI-052 and is awaiting top-line Phase 1b proof-of-concept data, while advancing ATI-2138 for lichen planus. Q1 revenue rose to $2.0 million from $1.5 million driven by higher royalties, but the company posted a net loss of $19.8 million versus $15.1 million a year earlier. » Więcej na finance.yahoo.com

Aclaris disclosed full phase‑1a results for ATI‑052: the bispecific antibody showed an estimated half‑life of about 45 days, dose‑proportional pharmacokinetics, sustained inhibition of relevant biomarkers and good tolerability with no safety signals. Recruitment for phase‑1b studies in asthma and atopic dermatitis is ongoing, with results expected in H2 2026 and a phase‑2b program for asthma planned for Q4 2026. In addition, Aclaris plans a phase‑2b basket study with the dual inhibitor ATI‑2138 in erosive mucosal and cutaneous lichen planus in H2 2026; there are currently no FDA‑approved therapies for lichen planus. » Więcej na de.investing.com